Page 4 - Nasdaq Fold News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...

StockNews.com cut shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a buy rating to a hold rating in a research report report published on Friday morning. Amicus Therapeutics Price Performance NASDAQ:FOLD opened at $12.92 on Friday. The stock has a market capitalization of $3.71 billion, a PE ratio of -20.19 and a beta of […]

PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...

Panagora Asset Management Inc. boosted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Free Report) by 9.9% during the 1st quarter, Holdings Channel.com reports. The firm owned 1,366,965 shares of the biopharmaceutical company’s stock after purchasing an additional 123,604 shares during the quarter. Panagora Asset Management Inc.’s holdings in Amicus Therapeutics were worth […]

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) from a hold rating to a buy rating in a report published on Thursday. Amicus Therapeutics Trading Up 1.4 % FOLD stock opened at $12.86 on Thursday. The company has a quick ratio of 2.40, a current ratio of 2.72 and a debt-to-equity ratio of […]